Patents by Inventor Mark A. Jensen
Mark A. Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210188975Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: June 28, 2020Publication date: June 24, 2021Applicant: Iterative Therapeutics, Inc.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20190055310Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: March 9, 2018Publication date: February 21, 2019Applicant: Iterative Therapeutics, Inc.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 10000819Abstract: This invention relates to a rapid method for detection and characterization of Escherichia coli bacteria serotype O157:H7 based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect E. coli O157:H7 in a food or water sample, such as a beef enrichment. The present invention further relates to replication compositions and kits for carrying out the method of the present invention.Type: GrantFiled: February 18, 2014Date of Patent: June 19, 2018Assignee: Qualicon Diagnostics LLCInventors: Daniel R. Demarco, Mark A. Jensen, Stephen Varkey
-
Patent number: 9528162Abstract: This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.Type: GrantFiled: July 8, 2014Date of Patent: December 27, 2016Assignee: E I DU PONT DE NEMOURS AND COMPANYInventors: Stephen Varkey, Daniel R. DeMarco, Mark A. Jensen
-
Publication number: 20160201116Abstract: This invention relates to a rapid, accurate method for detection and characterization of Salmonella enteritidis and/or Salmonella typhimurium based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect S. enteritidis and/or S. typhimurium in an environmental sample. The present invention further relates to replication compositions and kits for carrying out the method of the present invention.Type: ApplicationFiled: August 19, 2014Publication date: July 14, 2016Inventors: Mark A. Jensen, Daniel R. Demarco, Stephen Varkey, Jun Li
-
Publication number: 20160194395Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: August 6, 2015Publication date: July 7, 2016Applicant: ITERATIVE THERAPEUTICS, INC.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20150376686Abstract: This invention relates to a rapid method for detection and characterization of Escherichia coli bacteria serotype O157:H7 based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect E. coli O157:H7 in a food or water sample, such as a beef enrichment. The present invention further relates to replication compositions and kits for carrying out the method of the present invention.Type: ApplicationFiled: February 18, 2014Publication date: December 31, 2015Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: Daniel R. Demarco, Mark A. Jensen, Stephen Varkey
-
Publication number: 20150292039Abstract: Disclosed herein are methods for the identification of the species, serotype, and strain of a fungi. Also disclosed are primers for use in detecting such fungi and kits comprising such primers.Type: ApplicationFiled: April 7, 2015Publication date: October 15, 2015Inventors: Xuan Peng, Mark A. Jensen
-
Patent number: 9127063Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: GrantFiled: March 10, 2013Date of Patent: September 8, 2015Assignee: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 9040242Abstract: Disclosed herein are methods for the identification of the species, serotype, and strain of a microorganism. Also disclosed are primers for use in detecting such microorganisms and kits comprising such primers.Type: GrantFiled: July 19, 2012Date of Patent: May 26, 2015Assignee: E I DUPONT DE NEMOURS AND COMPANYInventors: Anjana Agarwal, Mark A. Jensen
-
Patent number: 8986698Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: GrantFiled: February 12, 2011Date of Patent: March 24, 2015Assignee: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20140323710Abstract: This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.Type: ApplicationFiled: July 8, 2014Publication date: October 30, 2014Inventors: Stephen Varkey, Daniel R. DeMarco, Mark A. Jensen
-
Patent number: 8802371Abstract: This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.Type: GrantFiled: September 28, 2012Date of Patent: August 12, 2014Assignee: E. I. du Pont de Nemours and CompanyInventors: Stephen Varkey, Daniel R. DeMarco, Mark A. Jensen
-
Publication number: 20130078634Abstract: This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.Type: ApplicationFiled: September 28, 2012Publication date: March 28, 2013Inventors: Stephen Varkey, Daniel R. DeMarco, Mark A. Jensen
-
Publication number: 20130029341Abstract: Disclosed herein are methods for the identification of the species, serotype, and strain of a microorganism. Also disclosed are primers for use in detecting such microorganisms and kits comprising such primers.Type: ApplicationFiled: July 19, 2012Publication date: January 31, 2013Inventors: Anjana AGARWAL, Mark A. Jensen
-
Patent number: 8163289Abstract: The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and nucleic acids used to encode the inventive polypeptides.Type: GrantFiled: March 6, 2008Date of Patent: April 24, 2012Assignee: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Publication number: 20110195067Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: February 12, 2011Publication date: August 11, 2011Applicant: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 7897729Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: GrantFiled: September 18, 2008Date of Patent: March 1, 2011Assignee: Iterative Therapeutics, Inc.Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
-
Patent number: 7655774Abstract: The present invention is directed to ancestral and COT nucleic acid and amino acid sequences, methods for producing such sequences and uses thereof, including prophylactic and diagnostic uses.Type: GrantFiled: February 17, 2004Date of Patent: February 2, 2010Assignee: University of WashingtonInventors: James I. Mullins, Allen G. Rodrigo, Gerald H. Learn, Fusheng Li, David C. Nickle, Mark A. Jensen
-
Publication number: 20090117133Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.Type: ApplicationFiled: September 18, 2008Publication date: May 7, 2009Applicant: ITERATIVE THERAPEUTICS, INC.Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White